PXS 4728A

Drug Profile

PXS 4728A

Alternative Names: PXS4728; PXS4728A; Semicarbazide‐sensitive amine oxidase/vascular adhesion protein‐1 inhibitor - Pharmaxis; SSAO/VAP‐1 inhibitor - Pharmaxis

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Pharmaxis
  • Developer Pharmaxis; University of Sydney
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease; Cystic fibrosis
  • Preclinical Asthma; Non-alcoholic steatohepatitis; Renal fibrosis

Most Recent Events

  • 15 May 2017 Boehringer Ingelheim plans a phase II trial for Non-alcoholic steatohepatitis by mid-year 2017
  • 15 May 2017 Boehringer Ingelheim plans a phase II trial in an undisclosed indication in 2017
  • 21 Sep 2015 Efficacy and adverse events data from a phase I trial in Chronic obstructive pulmonary disease and Cystic fibrosis (In volunteers) released by Pharmaxis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top